We are focused on building an innovative pipeline of differentiated therapies to benefit patients with liver and gastrointestinal diseases. Clinical trials are an important part of helping bring safe and effective medicines to patients.
All product candidates go through a rigorous series of clinical trials, and regulatory agencies, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency, decide whether to approve medicines based on the results of those trials.
For patients who lack effective treatments, clinical trials are also an opportunity to be a part of testing a new product candidate. By taking part in clinical trials, patients can make an important contribution to ongoing research and better understanding of a disease.
Check back at this website for information about upcoming clinical trials.
The FDA allows expanded access, sometimes referred to as “compassionate use,” as a potential pathway for a patient with an immediately life-threatening condition or serious disease to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. At this time, Metacrine believes access to its products should be limited to clinical trials and does not offer an expanded access program or accept expanded access requests.